Permissivity of the NCI-60 cancer cell lines to oncolytic Vaccinia Virus GLV-1h68

Permissivity of the NCI-60 cancer cell lines to oncolytic Vaccinia Virus GLV-1h68

Bibliographic Details
Main Authors:	Ascierto, Maria Libera, Worschech, Andrea, Yu, Zhiya, Adams, Sharon, Reinboth, Jennifer, Chen, Nanhai G, Pos, Zoltan, Roychoudhuri, Rahul, Di Pasquale, Giovanni, Bedognetti, Davide, Uccellini, Lorenzo, Rossano, Fabio, Ascierto, Paolo A, Stroncek, David F, Restifo, Nicholas P, Wang, Ena, Szalay, Aladar A, Marincola, Francesco M
Format:	Online
Language:	English
Published:	BioMed Central 2011
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3213037/

Similar Items

Growth inhibition of different human colorectal cancer xenografts after a single intravenous injection of oncolytic vaccinia virus GLV-1h68
by: Ehrig, Klaas, et al.
Published: (2013)

Oncolytic vaccinia virus GLV-1h68 strain shows enhanced replication in human breast cancer stem-like cells in comparison to breast cancer cells
by: Wang, Huiqiang, et al.
Published: (2012)

Efficient Colonization and Therapy of Human Hepatocellular Carcinoma (HCC) Using the Oncolytic Vaccinia Virus Strain GLV-1h68
by: Gentschev, Ivaylo, et al.
Published: (2011)

Evaluation of a New Recombinant Oncolytic Vaccinia Virus Strain GLV-5b451 for Feline Mammary Carcinoma Therapy
by: Adelfinger, Marion, et al.
Published: (2014)

Virotherapy of Canine Tumors with Oncolytic Vaccinia Virus GLV-1h109 Expressing an Anti-VEGF Single-Chain Antibody
by: Patil, Sandeep S., et al.
Published: (2012)

Preferential Colonization of Metastases by Oncolytic Vaccinia Virus Strain GLV-1h68 in a Human PC-3 Prostate Cancer Model in Nude Mice
by: Donat, Ulrike, et al.
Published: (2012)

Preclinical Testing Oncolytic Vaccinia Virus Strain GLV-5b451 Expressing an Anti-VEGF Single-Chain Antibody for Canine Cancer Therapy
by: Adelfinger, Marion, et al.
Published: (2015)

The stable traits of melanoma genetics: an alternate approach to target discovery
by: Spivey, Tara L, et al.
Published: (2012)

Vaccinia virus GLV-1h153 is a novel agent for detection and effective local control of positive surgical margins for breast cancer
by: Gholami, Sepideh, et al.
Published: (2013)

Targeting hematologic malignancies with oncolytic vaccinia virus constructs
by: Chen, Nanhai, et al.
Published: (2013)

IRF-1 responsiveness to immune cytokines predicts different cancer phenotypes
by: Murtas, Daniela, et al.
Published: (2013)

Microglia and astrocytes attenuate the replication of the oncolytic vaccinia virus LIVP 1.1.1 in murine GL261 gliomas by acting as vaccinia virus traps
by: Kober, Christina, et al.
Published: (2015)

Distinct signatures of the immune responses in low risk versus high risk neuroblastoma
by: Gowda, Madhu, et al.
Published: (2011)

The immune‐related role of BRAF in melanoma
by: Tomei, Sara, et al.
Published: (2014)

The immune-related role of BRAF in melanoma
by: Tomei, Sara, et al.
Published: (2015)

Replication efficiency of oncolytic vaccinia virus in cell cultures prognosticates the virulence and antitumor efficacy in mice
by: Chen, Nanhai G, et al.
Published: (2011)

Expression of anti-VEGF antibody together with anti-EGFR or anti-FAP enhances tumor regression as a result of vaccinia virotherapy
by: Huang, Ting, et al.
Published: (2015)

Association between HRAS rs12628 and rs112587690 polymorphisms with the risk of melanoma in the North American population
by: Tomei, Sara, et al.
Published: (2012)

Combination treatment with oncolytic Vaccinia virus and cyclophosphamide results in synergistic antitumor effects in human lung adenocarcinoma bearing mice
by: Hofmann, Elisabeth, et al.
Published: (2014)

An immunologic portrait of cancer
by: Ascierto, Maria Libera, et al.
Published: (2011)

Vaccinia virus-mediated intra-tumoral expression of matrix metalloproteinase 9 enhances oncolysis of PC-3 xenograft tumors
by: Schäfer, Simon, et al.
Published: (2012)

IRF-1 responsiveness to IFN-γ predicts different cancer immune phenotypes
by: Murtas, D, et al.
Published: (2013)

Vaccinia virus expressing bone morphogenetic protein-4 in novel glioblastoma orthotopic models facilitates enhanced tumor regression and long-term survival
by: Duggal, Rohit, et al.
Published: (2013)

Melanoma: From Incurable Beast to a Curable Bet. The Success of Immunotherapy
by: Ascierto, Maria Libera, et al.
Published: (2015)

HLA class I and II genotype of the NCI-60 cell lines
by: Adams, Sharon, et al.
Published: (2005)

A genetic inference on cancer immune responsiveness
by: Wang, Ena, et al.
Published: (2012)

Molecular network, pathway, and functional analysis of time-dependent gene changes associated with pancreatic cancer susceptibility to oncolytic vaccinia virotherapy
by: Haddad, Dana, et al.
Published: (2016)

Gene expression profiling in acute allograft rejection: challenging the immunologic constant of rejection hypothesis
by: Spivey, Tara L, et al.
Published: (2011)

Preclinical Evaluation of Oncolytic Vaccinia Virus for Therapy of Canine Soft Tissue Sarcoma
by: Gentschev, Ivaylo, et al.
Published: (2012)

Functional hyper-IL-6 from vaccinia virus-colonized tumors triggers platelet formation and helps to alleviate toxicity of mitomycin C enhanced virus therapy
by: Sturm, Julia B, et al.
Published: (2012)

Molecular signatures mostly associated with NK cells are predictive of relapse free survival in breast cancer patients
by: Ascierto, Maria Libera, et al.
Published: (2013)

Colonization of xenograft tumors by oncolytic vaccinia virus (VACV) results in enhanced tumor killing due to the involvement of myeloid cells
by: Kilinc, Mehmet Okyay, et al.
Published: (2016)

Meta-analysis and metagenes: CXCL-13-driven signature as a robust marker of intratumoral immune response and predictor of breast cancer chemotherapeutic outcome
by: Bedognetti, Davide, et al.
Published: (2014)

Combination therapy: the next opportunity and challenge of medicine
by: Ascierto, Paolo A, et al.
Published: (2011)

What have we learned from cancer immunotherapy in the last 3 years?
by: Ascierto, Paolo A, et al.
Published: (2014)

2015: The Year of Anti-PD-1/PD-L1s Against Melanoma and Beyond
by: Ascierto, Paolo A., et al.
Published: (2015)

Doxycycline Inducible Melanogenic Vaccinia Virus as Theranostic Anti-Cancer Agent
by: Kirscher, Lorenz, et al.
Published: (2015)

Intratumoral INF-γ triggers an antiviral state in GL261 tumor cells: a major hurdle to overcome for oncolytic vaccinia virus therapy of cancer
by: Kober, Christina, et al.
Published: (2015)

Imaging Characteristics, Tissue Distribution, and Spread of a Novel Oncolytic Vaccinia Virus Carrying the Human Sodium Iodide Symporter
by: Haddad, Dana, et al.
Published: (2012)

Optical Detection and Virotherapy of Live Metastatic Tumor Cells in Body Fluids with Vaccinia Strains
by: Wang, Huiqiang, et al.
Published: (2013)